Canadian Patent Allowance Expands Coverage for RosettaGX Reveal™ Thyroid MicroRNA Classifier
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / July 6, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics
company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that it
has expanded its global patent portfolio with the following patent office grants and notification:
- The Canadian Intellectual
Property Office has granted a patent allowance for CA Patent Application No. 2,945,531, relating to "miRNA Expression Signature in
the Classification of Thyroid Tumors," which claims a method of classifying a thyroid lesion sample obtained by fine needle
aspiration as malignant or benign, through a classifier algorithm that utilizes the expression profile of microRNAs. - The United
States Patent and Trademark Office has granted a patent allowance for US Patent Application No. 14/284,256, which claims a method
of distinguishing between primary and metastatic gastrointestinal tumor, through the expression profile of microRNAs. - The Chinese
Patent Office has issued a notification to grant a patent for CN Patent Application No. 201280025062.7, relating to "Methods and
Compositions for Determining Heart Failure and or a Risk of Heart Failure," which claims the use of a primer or a probe for
detecting microRNAs in the manufacture of a kit for diagnosing or prognosticating chronic heart failure in a subject.
"We remain committed to fortifying our global leadership in microRNA intellectual property, and these patent actions further
strengthen that position," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Near-term, we are
focused on U.S. commercial efforts for RosettaGX Reveal™, our thyroid microRNA classifier for the diagnosis of cancer in
indeterminate thyroid nodules, and on international expansion of this assay through distributors such as our recently-formed
relationships with Rhenium in Israel and Cytolog in Brazil. As we look to expand further in other geographies, this Canadian patent
allowance will help in this endeavor."
About Rosetta Genomics
Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables
physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of
unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to help them
deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid
nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects including, but not limited to
statements relating to fortifying our global leadership in microRNA intellectual property, expanding internationally, focusing on
US commercial efforts for RosettaGX Reveal™ and statements containing the words "expect," "believe," "will," "may," "should,"
"project," "estimate," "anticipated," "scheduled," and like expressions, and the negative thereof, constitute forward-looking
statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking statements as a result of various risks and
uncertainties, including, but are not limited to the following: we will require substantial additional funds to continue our
operations and, if additional funds are not available, we may need to significantly scale back or cease our operations; we have a
history of losses and may never be profitable; if we are unable to expand sales of our diagnostic tests in the United States, it
would have a material adverse effect on our business and financial condition; if we are unable to find profitable strategic
alternatives for our PersonalizeDx diagnostic testing and services business, it would have a material adverse effect on our
business and financial condition; the intensely competitive biotechnology market could diminish demand for our tests and products;
the market may not be receptive to any diagnostic tests or therapeutic products using our microRNA technology; we currently have
limited sales, marketing or distribution experience and may in the future depend significantly on third parties to commercialize
microRNA-based diagnostic tests or therapeutic products we may develop; we are largely dependent upon our distributors for the
success of commercialization of our current diagnostic tests; health insurers and other third-party payors may decide not to cover
our diagnostic products or may provide inadequate reimbursement, which could jeopardize our commercial prospects; because of
Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients; if we fail to comply with our
obligations under any licenses or related agreements, we could lose license rights that may be necessary for developing
microRNA-based diagnostics and therapeutics; if we fail to comply with the complex federal, state, local and foreign laws and
regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our
operating results and financial condition; we contract with a single manufacturer for the purchase of microarray chips for certain
tests, and the failure of this manufacturer to supply sufficient quantities on a timely basis could have a material adverse effect
on our business; and other risk factors discussed under the heading "Risk Factors" in Rosetta's most recently filed Annual Report
on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of
this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.
Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of Rosetta's most recently filed Annual Report on Form
20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this
release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation
to update any forward-looking statements unless required by law.
Rosetta Genomics Contact:
Ken Berlin, President & CEO (267) 298-1159 investors@rosettagx.com
Rosetta Genomics Investor Contact:
LHA Anne Marie Fields (212) 838-3777 afields@lhai.com
SOURCE: Rosetta Genomics Ltd.
